Avalon GloboCare (US:ALBT) — Company Overview, News & Financial Data
Avalon GloboCare is a biotechnology company advancing cellular therapeutics and diagnostics for cancer and infectious diseases.
Avalon GloboCare
Avalon GloboCare (NASDAQ:ALBT) is a dynamic biotechnology company devoted to advancing innovative cellular therapeutics and diagnostics to combat a wide range of diseases, including cancer and infectious diseases. With a keen focus on cell-based technologies, Avalon GloboCare is engaged in developing cutting-edge therapies and medical solutions that aim to redefine healthcare treatment paradigms. The company's objectives are centered on expediting the clinical development of its flagship products, making significant strides in cellular immunotherapy, and expanding its global research and development footprint to bring transformative healthcare solutions to patients worldwide.
Snapshot
Operations
Products and/or services of Avalon GloboCare
- Exosome-based therapeutics and diagnostics targeting cancer and other diseases.
- Cellular immunotherapy for cancer and immune disorders.
- Regenerative medicine, focusing on tissue engineering and stem cell therapy.
- Digital health solutions, including AI-driven diagnostic and therapeutic tools.
- Clinical laboratory services providing diagnostics and early disease detection.
- Partnerships for developing and commercializing innovative healthcare technologies.
Avalon GloboCare executive team
- Ms. Meng LiInterim CEO & COO
- Ms. Luisa IngargiolaChief Financial Officer